PE119199A1 - Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica - Google Patents
Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronicaInfo
- Publication number
- PE119199A1 PE119199A1 PE1998000882A PE00088298A PE119199A1 PE 119199 A1 PE119199 A1 PE 119199A1 PE 1998000882 A PE1998000882 A PE 1998000882A PE 00088298 A PE00088298 A PE 00088298A PE 119199 A1 PE119199 A1 PE 119199A1
- Authority
- PE
- Peru
- Prior art keywords
- rna
- infection
- chronic hepatitis
- alpha
- patients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
SE REFIERE AL USO JUNTO O SEPARADO DE a)RIBAVIRINA UTILIZANDOSE 400-1200 mg/DIA; b)INTERFERON ALFA UTILIZANDOSE DE 2-10 MILLONES UI; PARA LA FABRICACION DE UNA COMPOSICION QUE PUEDE SER UTIL PARA TRATAR UNA INFECCION POR HEPATITIS C CRONICA Y ERRADICAR EL VHC-ARN DETECTABLE, O UNA CARGA VIRAL MAYOR DE 2 MILLONES POR MILILITRO DE SUERO, MEDIDA POR PRC CUANTITATIVA DEL VHC-ARN. EL INTERFERON ALFA ES DE PREFERENCIA INTERFERON ALFA-2a, INTERFERON ALFA 2-b, INTERFERON ALFA CONSENSUAL, UN PRODUCTO DE INTERFERON ALFA PURIFICADO, INTERFERON ALFA PEGILADO
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/938,033 US6172046B1 (en) | 1997-09-21 | 1997-09-21 | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
US93512397A | 1997-09-22 | 1997-09-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE119199A1 true PE119199A1 (es) | 1999-12-01 |
Family
ID=27130070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1998000882A PE119199A1 (es) | 1997-09-21 | 1998-09-16 | Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica |
Country Status (24)
Country | Link |
---|---|
EP (3) | EP0903148B1 (es) |
JP (1) | JPH11152231A (es) |
KR (1) | KR20010024188A (es) |
CN (1) | CN1250283C (es) |
AR (1) | AR013497A1 (es) |
AT (2) | ATE206618T1 (es) |
AU (1) | AU749924B2 (es) |
BR (1) | BR9812484A (es) |
CA (1) | CA2245938C (es) |
CO (1) | CO4970691A1 (es) |
DE (2) | DE69801970T2 (es) |
DK (2) | DK0903148T3 (es) |
ES (2) | ES2162393T3 (es) |
HK (2) | HK1016505A1 (es) |
HU (1) | HUP0100092A3 (es) |
IL (1) | IL134428A0 (es) |
MY (1) | MY117781A (es) |
NO (1) | NO20001437L (es) |
NZ (1) | NZ502740A (es) |
PE (1) | PE119199A1 (es) |
PT (1) | PT903148E (es) |
SK (1) | SK3922000A3 (es) |
TW (1) | TW568787B (es) |
WO (1) | WO1999015194A1 (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2172288T3 (es) * | 1998-05-15 | 2002-09-16 | Schering Corp | Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c. |
JP2003507322A (ja) * | 1998-12-18 | 2003-02-25 | シェリング・コーポレーション | リバビリン−PEG化インターフェロン−α誘発HCV併用治療 |
AR022116A1 (es) * | 1998-12-18 | 2002-09-04 | Schering Corp | Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa |
DE19919585A1 (de) | 1999-04-29 | 2000-12-07 | Cmi Ag | Verwendung von Phyllanthus zur Behandlung von oxidativem Streß und anderen Symptomen |
CA2405709A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
CA2410579C (en) | 2000-05-26 | 2010-04-20 | Jean-Pierre Sommadossi | Methods and compositions for treating flaviviruses and pestiviruses |
US7208167B2 (en) | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
EP1330468B1 (en) | 2000-09-18 | 2007-08-01 | Applied Research Systems ARS Holding N.V. | Sulphur analogues of 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) for treating excess of glucocorticoids |
CA2471363C (en) | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
ES2469569T3 (es) | 2002-06-28 | 2014-06-18 | Idenix Pharmaceuticals, Inc. | Prof�rmacos de nucle�sidos modificados en 2' y 3' para el tratamiento de infecciones de Flaviviridae |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
RS113904A (en) | 2002-06-28 | 2007-02-05 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
JP2004155777A (ja) * | 2002-10-16 | 2004-06-03 | Asahi Kasei Pharma Kk | C型慢性肝炎治療剤 |
CN1849142A (zh) | 2002-11-15 | 2006-10-18 | 埃迪尼克斯(开曼)有限公司 | 2′-支链核苷和黄病毒突变 |
RU2358979C2 (ru) | 2003-05-30 | 2009-06-20 | Фармассет, Инк. | Модифицированные фторированные аналоги нуклеозида |
ZA200601181B (en) * | 2003-08-13 | 2007-04-25 | Smith Howard J & Ass Pty Ltd | Method of treating viral infections |
ES2245248B1 (es) * | 2004-06-09 | 2007-02-16 | Universidad De Salamanca | Uso de la artemisinina y sus derivados en la fabricacion de medicamentos utiles como agentes antiviricos. |
KR101177590B1 (ko) | 2004-09-14 | 2012-08-27 | 파마셋 인코포레이티드 | 2'-플루오로-2'-알킬 치환되거나 또는 다른 선택적으로치환된 리보퓨라노실 피리미딘 및 퓨린 및 그 유도체의제조 |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
US8137661B2 (en) | 2007-07-25 | 2012-03-20 | Biolex Therapeutics, Inc. | Controlled release interferon drug products and treatment of HCV infections using same |
TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
KR20110104074A (ko) | 2008-12-23 | 2011-09-21 | 파마셋 인코포레이티드 | 퓨린 뉴클레오시드의 합성 |
PA8855601A1 (es) | 2008-12-23 | 2010-07-27 | Forformidatos de nucleósidos | |
US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
CN102458470B (zh) | 2009-05-08 | 2016-01-20 | 赛生制药有限公司 | 作为疫苗增强剂的α胸腺素肽 |
TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
CA2794671C (en) | 2010-03-31 | 2018-05-01 | Gilead Pharmasset Llc | Stereoselective synthesis of phosphorus containing actives |
WO2012075140A1 (en) | 2010-11-30 | 2012-06-07 | Pharmasset, Inc. | Compounds |
CN106166160A (zh) | 2011-09-16 | 2016-11-30 | 吉利德制药有限责任公司 | 用于治疗hcv的组合物 |
ES2572329B1 (es) | 2011-10-21 | 2017-08-24 | Abbvie Inc. | Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
BR112014005617A2 (pt) | 2011-10-21 | 2017-06-13 | Abbvie Inc | tratamento de combinação (por exemplo, com abt-072 ou abt -333) de daas para uso no tratamento de hcv |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
US20140212491A1 (en) | 2013-01-31 | 2014-07-31 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
EP4005560A1 (en) | 2013-08-27 | 2022-06-01 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
WO2015136455A1 (en) * | 2014-03-13 | 2015-09-17 | Novartis Ag | New treatments of hepatitis c virus infection |
WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
-
1998
- 1998-08-07 DE DE69801970T patent/DE69801970T2/de not_active Revoked
- 1998-08-07 ES ES98306332T patent/ES2162393T3/es not_active Expired - Lifetime
- 1998-08-07 DK DK98306332T patent/DK0903148T3/da active
- 1998-08-07 AT AT98306332T patent/ATE206618T1/de not_active IP Right Cessation
- 1998-08-07 PT PT98306332T patent/PT903148E/pt unknown
- 1998-08-07 DE DE69810822T patent/DE69810822T2/de not_active Revoked
- 1998-08-07 EP EP98306332A patent/EP0903148B1/en not_active Revoked
- 1998-08-07 EP EP01113628A patent/EP1136075B1/en not_active Revoked
- 1998-08-07 EP EP02026486A patent/EP1317929A3/en not_active Withdrawn
- 1998-08-07 DK DK01113628T patent/DK1136075T3/da active
- 1998-08-07 ES ES01113628T patent/ES2186660T3/es not_active Expired - Lifetime
- 1998-08-07 AT AT01113628T patent/ATE230999T1/de not_active IP Right Cessation
- 1998-08-26 CA CA002245938A patent/CA2245938C/en not_active Expired - Lifetime
- 1998-09-16 SK SK392-2000A patent/SK3922000A3/sk unknown
- 1998-09-16 AU AU94737/98A patent/AU749924B2/en not_active Withdrawn - After Issue
- 1998-09-16 IL IL13442898A patent/IL134428A0/xx unknown
- 1998-09-16 KR KR1020007002960A patent/KR20010024188A/ko not_active Application Discontinuation
- 1998-09-16 BR BR9812484-6A patent/BR9812484A/pt not_active Application Discontinuation
- 1998-09-16 CN CNB988093502A patent/CN1250283C/zh not_active Expired - Lifetime
- 1998-09-16 TW TW087115445A patent/TW568787B/zh not_active IP Right Cessation
- 1998-09-16 PE PE1998000882A patent/PE119199A1/es not_active Application Discontinuation
- 1998-09-16 NZ NZ502740A patent/NZ502740A/xx not_active IP Right Cessation
- 1998-09-16 AR ARP980104602A patent/AR013497A1/es unknown
- 1998-09-16 MY MYPI98004234A patent/MY117781A/en unknown
- 1998-09-16 WO PCT/US1998/018488 patent/WO1999015194A1/en not_active Application Discontinuation
- 1998-09-16 HU HU0100092A patent/HUP0100092A3/hu unknown
- 1998-09-17 CO CO98053709A patent/CO4970691A1/es unknown
- 1998-09-21 JP JP10266599A patent/JPH11152231A/ja active Pending
-
1999
- 1999-04-17 HK HK99101676A patent/HK1016505A1/xx not_active IP Right Cessation
-
2000
- 2000-03-20 NO NO20001437A patent/NO20001437L/no not_active Application Discontinuation
-
2002
- 2002-03-21 HK HK02102185.9A patent/HK1041440B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE119199A1 (es) | Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica | |
AR012614A1 (es) | Una composicion farmaceutica para la fabricacion de un medicamento destinado para el tratamiento de una infeccion viral susceptible de tratamientocon interferon alfa, un metodo para la fabricacion de un medicamento, el uso de peg12000-ifn alfa para la fabricacion de un medicamento | |
AR019551A1 (es) | Uso de la ribavirina en combinacion con el interferon alfa para la fabricacion de un medicamento para la terapia de combinacion para erradicar hcv-rna detectable en pacientes no afectados a tratamiento antiviral que tienen infeccion de hepatitis c cronica | |
AR021876A1 (es) | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado | |
AR016798A1 (es) | Uso de una cepa de lactobacillus para la elaboracion de un medicamento | |
BR9811121A (pt) | Produto, composição farmacêutica, e uso de um produto | |
BR0114636A (pt) | Terapia combinada para hcv de interferon-alfa peguilado/ribavirina | |
BR0010593A (pt) | Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv | |
EA200200812A1 (ru) | Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение | |
NZ330784A (en) | Modulation of th1/th2 cytokine expression by ribavirin and ribavirin analogs in activated t-lymphocytes | |
PE20001386A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa | |
BR0108997A (pt) | Terapia imune adjuvante para hiv | |
MD990258A (en) | Method of treatment of the acute viral hepatitis B | |
AR029160A1 (es) | El uso del interferon-alfa pegilado para la preparacion de un medicamento para el tratamiento del carcinoma de celula renal, un kit y el uso del mismo | |
AU5535498A (en) | Treatment of HIV positive patients | |
ES2160927T3 (es) | Composiciones farmaceuticas que comprenden interferon alfa humano natural. | |
TR200000728T2 (tr) | Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı. | |
Mascolini | Protease inhibitor update: treatment combination strategies | |
ATE269063T1 (de) | Formulierungen zur transdermalen verabreichung von fenoldopam | |
ECSP003462A (es) | Terapia de hiv de combinacion de antagonista ccr5 - interferon alfa pegilado (caso ino1024k) | |
Highleyman | Twice-daily indinavir dosing not recommended | |
ECSP982669A (es) | Terapia en combinacion para erradicar vhc -arn detectable en pacientes que padecen infeccion de hetatitis c cronica | |
Simmons | Dressing up your virus: a new outfit for HIV | |
Baker | Advantages of HIV treatment with Hydrea (Hydroxyurea) | |
ATE332704T1 (de) | Behandlung von hepatitis c mit thymosin und pegyliertem interferon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |